Avricore Health Inc.

What they do

Avricore Health Inc., listed on the TSXV as AVCR, is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its wholly owned subsidiary HealthTab, the company provides a turnkey point-of-care testing platform intended to create value for stakeholders and better outcomes for patients. The company has been a reporting issuer in British Columbia, Canada since 2000 and has undergone several name changes, most recently to Avricore Health Inc. in November 2018.

Revenue drivers

• HealthTab point-of-care testing platform — HealthTab is the company's flagship offering, a lab-accurate point-of-care testing platform provided as a turnkey system to pharmacies. The filing does not break out revenue by segment or disclose specific customer contracts or revenue amounts.

Recent performance

The provided financial data shows annual net losses from 2017 through 2020: $1.3 million in 2017, $3.5 million in 2018, $1.9 million in 2019, and $1.2 million in 2020. No revenue figures or results for 2021 through 2024 are included in the source material. The 2025 annual report on Form 20-F covers the fiscal year ended December 31, 2024, but the excerpts provided do not contain the financial statements or MD&A discussion of results.

Strategy

Management describes Avricore as a pharmacy service innovator focused on acquiring and developing early-stage technologies to advance pharmacy practice. The strategy centers on its wholly owned subsidiary HealthTab and its turnkey point-of-care testing platform, which the company positions as creating value for stakeholders and better patient outcomes. The filing does not disclose specific investment plans, partnership targets, or capital allocation priorities beyond this general description.

Risks

• History of net losses — The company reported net losses in each year from 2017 to 2020, including a $3.5 million loss in 2018, and may continue to incur losses.
• Limited revenue disclosure — The provided excerpts do not disclose any revenue figures or customer contracts, making it difficult to assess the commercial traction of HealthTab.
• Dependence on a single platform — The business is concentrated in the HealthTab point-of-care testing platform, with no other significant revenue sources identified in the filing.
• Regulatory and reimbursement uncertainty — As a point-of-care testing platform for pharmacies, HealthTab may be subject to changing healthcare regulations and reimbursement policies that could affect adoption.

Outlook

The provided excerpts do not include management's forward-looking statements or guidance. The company's Form 20-F for fiscal year 2024 states that the annual report contains forward-looking statements, but no specific outlook or projections are summarized in the source material provided.